Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S, Balian A, Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Bailly F, Chaumet-Riffaud P, Emilie D. Naveau S, et al. Among authors: daurat v. J Hepatol. 1999 Oct;31(4):612-7. doi: 10.1016/s0168-8278(99)80339-0. J Hepatol. 1999. PMID: 10551383 Clinical Trial.
A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group.
Poynard T, Daurat V, Chevret S, Moussalli J, Degos F, Bailly F, Borotto E, Buffet C, Bartolomei-Portal I, Richardet JP, Riachi G, Calmus Y, Bréchot C, Vidaud M, Olivi M, Bedossa P, Riffaud PC, Chastang C. Poynard T, et al. Among authors: daurat v. J Viral Hepat. 1999 Sep;6(5):381-6. doi: 10.1046/j.1365-2893.1999.00170.x. J Viral Hepat. 1999. PMID: 10607254 Clinical Trial.
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group.
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Degos F, et al. Among authors: daurat v. J Hepatol. 1998 Aug;29(2):224-32. doi: 10.1016/s0168-8278(98)80007-x. J Hepatol. 1998. PMID: 9722203 Clinical Trial.
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group. Poynard T, et al. Among authors: daurat v. J Viral Hepat. 2003 May;10(3):197-204. doi: 10.1046/j.1365-2893.2003.00427.x. J Viral Hepat. 2003. PMID: 12753338 Clinical Trial.
Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study.
Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Métro A, Giraudeau B, Preux PM, Tréluyer JM, Chevret S, Plättner V, Thalamas C, Clisant S, Ravaud P, Chêne G; Optimon Collaborative Group. Journot V, et al. Among authors: daurat v. Contemp Clin Trials. 2011 Jan;32(1):16-24. doi: 10.1016/j.cct.2010.10.001. Epub 2010 Oct 14. Contemp Clin Trials. 2011. PMID: 20951234
13 results